Polyclonal antilymphocyte/antithymocyte globulin that depletes T cells.
Polyclonal anti–T-lymphocyte immunoglobulin that binds multiple T‑cell surface antigens and induces complement-dependent cytotoxicity and Fc-mediated clearance (ADCC/phagocytosis), leading to rapid T‑cell depletion and immunosuppression.
ATG binds CD18 (LFA-1) on T cells and induces complement-dependent lysis and Fc-mediated effector killing (ADCC/phagocytosis), depleting the bound cells.
Polyclonal antilymphocyte/antithymocyte globulin that depletes T cells.
Polyclonal anti–T-lymphocyte immunoglobulin that binds multiple T‑cell surface antigens and induces complement-dependent cytotoxicity and Fc-mediated clearance (ADCC/phagocytosis), leading to rapid T‑cell depletion and immunosuppression.
ATG antibodies bind CD28 on T cells and induce complement-dependent lysis and Fc receptor–mediated ADCC/phagocytosis, directly depleting CD28+ cells.
Polyclonal antilymphocyte/antithymocyte globulin that depletes T cells.
Polyclonal anti–T-lymphocyte immunoglobulin that binds multiple T‑cell surface antigens and induces complement-dependent cytotoxicity and Fc-mediated clearance (ADCC/phagocytosis), leading to rapid T‑cell depletion and immunosuppression.
ATG antibodies bind CD45 on T cells, activating complement-mediated lysis and Fc-dependent ADCC/phagocytosis, causing rapid T-cell depletion.
Polyclonal antilymphocyte/antithymocyte globulin that depletes T cells.
Polyclonal anti–T-lymphocyte immunoglobulin that binds multiple T‑cell surface antigens and induces complement-dependent cytotoxicity and Fc-mediated clearance (ADCC/phagocytosis), leading to rapid T‑cell depletion and immunosuppression.
ATG contains antibodies that bind HLA-DR on the cell surface and induce complement-dependent lysis and Fc-mediated ADCC/phagocytosis, depleting HLA-DR–positive cells.
Aumolertinib (HS-10296; almonertinib) is an oral, third-generation, irreversible EGFR tyrosine kinase inhibitor selective for activating EGFR mutations, inhibiting downstream MAPK and PI3K/AKT signaling.
Third-generation, irreversible EGFR tyrosine kinase inhibitor selective for mutant EGFR (e.g., Ex19del, L858R, T790M). Covalently inhibits EGFR kinase activity, blocking autophosphorylation and downstream MAPK and PI3K/AKT signaling, resulting in growth inhibition and apoptosis of EGFR-mutant tumor cells.
Aumolertinib covalently inhibits mutant EGFR (exon 19 deletion), blocking autophosphorylation and MAPK/PI3K-AKT signaling, leading to growth inhibition and apoptosis of EGFR-mutant tumor cells.